At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...
A new review of preclinical studies suggests GLP-1 drugs like Ozempic may reduce key proteins linked to Alzheimer’s disease.
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
The sub-study examined the impact of the therapy on prespecified Alzheimer’s plasma biomarkers in the subjects. Credit: ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
A new study shows that changes linked to Alzheimer’s disease can speed up with age in people’s late 50s, long before memory ...
The Alzheimer's Arkansas Champions Award Luncheon on April 23 at Arkansas Federal Credit Union recognized the efforts of ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...
Researchers have identified a new potential weapon against Alzheimer’s: blocking a protein called PTP1B. In mice, this approach boosted memory and helped brain immune cells clear harmful plaque ...
MedPage Today on MSN
FDA Approves First Non-Antipsychotic Drug for Alzheimer's Agitation
Oral NMDA receptor antagonist gets an expanded indication ...
Scientists have discovered a way to help the brain clean itself of harmful Alzheimer’s plaques by activating its own support cells. By increasing a protein called Sox9, researchers were able to boost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results